Fresh Tracks Therapeutics Profit Margin

Fresh Tracks Therapeutics (FRTX) currently reports a profit margin of -70.35% as of December 2023. That compares with -303.93% in the prior-year period — up 76.9% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Fresh Tracks Therapeutics's profit margin history and peer comparisons.

Fresh Tracks Therapeutics's profit margin increased from -303.93% to -70.35% — a 76.9% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fresh Tracks Therapeutics's profit margin of -70.35% is lower than the Healthcare sector average of 14.34%. That is roughly 590.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Fresh Tracks Therapeutics's current -70.35% should be judged against Healthcare norms (sector average: 14.34%) and against FRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -70.35%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Fresh Tracks Therapeutics, and consider following FRTX for alerts when major investors trade the stock.